Assessing the breakdown of commercial agreements – bad luck or poor performance?
For companies across several industries, product development and commercialization are risky endeavors. Companies often employ commercial agreements with...
Dr. Peter J. Rankin, Vice President, has been a member of CRA’s Life Sciences Practice since 1999, specializing in economic and strategic evaluation.
His pharmaceutical research includes assessment of patent extension antitrust claims, class certification analysis, monetary damages from commercial and intellectual property disputes, international arbitration involving contract disputes, abbreviated new drug applications (ANDAs), and product reimbursement strategies. In addition, Dr. Rankin has authored public and proprietary policy evaluation projects involving healthcare reform, reimbursement methodologies, antitrust exemptions, research and development incentives, and research productivity. Dr. Rankin has served as an expert in litigation and arbitration, and has testified before Congress.
While a doctoral candidate at Duke University, Dr. Rankin was a researcher at the Center for Health Policy, Law, and Management, where he published papers on hospital conversions; medical malpractice; and managed care quality, satisfaction, and participation. His dissertation research evaluated pricing and product differentiation in the Medicare-managed care market.